ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0651

Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares

Luigi Brunetti1, Janaki Vekaria1, Peter Lipsky2 and Naomi Schlesinger3, 1Rutgers Ernest Mario School of Pharmacy, piscataway, NJ, 2AMPEL BioSolutions LLC., Charlottesville, VA, 3Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

Meeting: ACR Convergence 2020

Keywords: gout

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Saturday, November 7, 2020

Session Title: Metabolic & Crystal Arthropathies Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout is the most common inflammatory arthritis and its economic burden is substantial, with estimates for the overall cost exceeding $20 billion (US) annually. Contributing to the economic burden are hospital admissions and iatrogenic events associated with pharmacotherapy.  Identification of modifiable risk factors would be an important contribution to clinical practice.

The purpose of this study was to identify opportunities for enhancing gout care in patients presenting to the Emergency Department (ED) with gout flares.

Methods: This retrospective cohort study used data from electronic medical records (EMR) at a large community hospital. All consecutive patients visiting the medical center ED with a primary diagnosis of gout from 1/1/2016 to 7/1/2019 were included.  Patients were then followed for 90 days to determine whether they were readmitted to the ED for any reason.  A chart review identified whether they were on appropriate medications in terms of gout flare management. All data were summarized using descriptive statistics.  A multiple logistic regression was constructed to identify risk factors for ED utilization within 90 days of the index visit.

Results: A total of 214 patients were included in the analysis.  Most patients were male (79%), mean age was 59.4 ± 15.6 years, and mean Charlson comorbidity index was 0.5 ± 1.14.  The most common medications prescribed during the ED visit included NSAIDs (41.6%), opioids (28%), corticosteroids (26.6%), and colchicine (21%).  Allopurinol and febuxostat were initiated in the ED in 4.7% and 0.9%, respectively.  Discharge medications for the management of gout included NSAIDs (37%), corticosteroids (34.6%), opioids (23.8%), colchicine (14%), febuxostat (7%), and allopurinol (6.5%).  Of the patients sent home with an opioid, 40% were newly prescribed.  An anti-inflammatory medication was not prescribed in 29.6% of patients discharged from the ED. Readmission within 90 days was recorded in 16.8% of patients. Of these readmissions, 33.3% were gout-related and 11.1% were cardiac related. 

After adjusting for age and comorbidity index, patients receiving colchicine were 2.8 times more likely (OR, 2.81; 95% CI, 1.12 to 7.02; p=0.027) to return to the ED within 90 days.  The most common cause of readmission in this subset was gout-related (54.5%).

Conclusion: Approximately  30% of patients were discharged from the ED without an anti-inflammatory medication, whereas initiation of urate lowering therapy was rare. Opiates were used frequently, but the indication was uncertain. Only 5.6% of subjects revisited the ED for gout-related diagnoses in the subsequent 3 months. Colchicine prescription was associated with an increased risk of gout-related ED utilization within 90 days. Treatment of gout in the ED is sub-optimal and often does not follow established guidelines.


Disclosure: L. Brunetti, CSL Behring, 2, Astellas Pharma, 2, Horizon Blue Cross Blue Shield of New Jersey, 5; J. Vekaria, None; P. Lipsky, Horizon Therapeutics, 3; N. Schlesinger, Johnson and Johnson, 5, Horizon, 5, IFM, 5, Pfizer, 2, AMGEN, 2.

To cite this abstract in AMA style:

Brunetti L, Vekaria J, Lipsky P, Schlesinger N. Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/readmission-risk-and-quality-of-care-in-patients-presenting-to-the-emergency-department-with-gout-flares/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/readmission-risk-and-quality-of-care-in-patients-presenting-to-the-emergency-department-with-gout-flares/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.